American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert | Latest News RSS feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert - Latest News


ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

A new ... American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with ... read more

Cardiology association recommends Lilly's Jardiance for lowering CV risk in type 2 diabetics

and alliance partner Boehringer Ingelheim announce that the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for reducing cardiovascular (CV) ... read more

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

“There is an urgent need for treatment options that can improve cardiovascular-related outcomes in people with type 2 diabetes and peripheral artery disease ... American College of Cardiology (ACC) re... read more

Looking for another news?


ACC offers guidance on using diabetes drugs for CV event reduction

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients w... read more


LLY Apr 2015 72.500 call

PR Newswire•13 hours ago American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Conse... read more

Diabetes and Lipid Management

The 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol expanded the indications for statin therapy for the prevention o... read more

Bolstering your armamentarium with SGLT2 inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are newer agents available for the treatment of type 2 diabetes ... indication for empagliflozin to include the reduction of cardiovascular death risk ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Empagliflozin is an effective and well-established medicine used to treat adults with type 2 diabetes ... A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) rec... read more

H.I.G. Capital Invests in Prime Office Building in Milan

Based in Miami, and with offices in New York, Boston, Chicago ... outs of both profitable as well as underperforming manufacturing and service businesses. 2. H.I.G.’s debt funds invest in senior, unit... read more

ELI LILLY (LLY.BE)

INGELHEIM, Germany and INDIANAPOLIS, Ind. , Nov. 27, 2018 /PRNewswire/ -- A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the pre... read more

The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease

Persistent increased UAE (30 mg/g to 299 mg/g) is a well-established marker for the development of DKD and increased cardiovascular disease (CVD ... and American College of Endocrinology on the Compre... read more

H.I.G. Capital Invests in Logistics Assets in Denmark

Based in Miami, and with offices in New York, Boston, Chicago ... outs of both profitable as well as underperforming manufacturing and service businesses. 2. H.I.G.’s debt funds invest in senior, unit... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us